Ipamorelin
Also known as: IPAM, NNC 26-0161
A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin. Considered one of the safest GHRPs.
Mechanism of Action
Ipamorelin binds to ghrelin receptors (GHSR) in the pituitary gland, triggering growth hormone release. Unlike other GHRPs, it does not stimulate significant ACTH, cortisol, prolactin, or aldosterone release, making it highly selective for GH.
Research Summary
Clinical studies show dose-dependent GH release with minimal side effects. Research demonstrates improved bone density in postmenopausal women and potential benefits for muscle mass and recovery. Has been studied for post-surgical recovery.
Research Protocols
Note: Doses observed in research studies
Common Doses
- •100-300 mcg per injection
- •200-300 mcg 2-3x daily
Duration
8-12 weeks typical
Administration
Subcutaneous injection
Side Effects & Considerations
- •Headache
- •Flushing
- •Dizziness
- •Transient water retention
- •Increased hunger
- •Generally mild side effect profile
References
Want updates on Ipamorelin research?
Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.
Educational Information Only
This information is provided for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare providers before making any decisions about peptides or other substances. The protocols listed reflect doses observed in research studies, not recommendations.